Patent ID: 11952418
Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treatment of tumors expressing human LRP5 and/or human LRP6 by inhibition of the Wnt-1 and/or Wnt-3a signaling pathways in a cancer patient comprising administering to said patient a cross-reactive biparatopic polypeptide which specifically binds to an epitope of the human low-density receptor-like protein 5 (LRP5) as well as an epitope of the human low-density receptor-like protein 6 (LRP6) in an amount effective to reduce said patient's tumor burden and/or tumor size wherein said cross-reactive biparatopic polypeptide comprises:
(a) a first immunoglobulin single variable domain, wherein said immunoglobulin single variable domain is a humanized VHH domain capable of inhibiting the Wnt1 signaling pathway comprising the CDR sequences:, (SEQ ID NO: 4)

CDR1: SYAMG

 

(SEQ ID NO: 5)

CDR2: AIRRSGRRTYYADSVKG

and

 

(SEQ ID NO: 6)

CDR3: ARRVRSSTRYNTGTWWWEY;

and
(b) a second immunoglobulin single variable domain wherein said second immunoglobulin single variable domain is a humanized VHH domain capable of inhibiting the Wnt3a signaling pathway comprising the following CDR sequences:, (SEQ ID NO: 13)

CDR1: SYAMG

 

(SEQ ID NO: 14)

CDR2: AISWRSGSTYYADSVKG

and

 

(SEQ ID NO: 15)

CDR3: DPRGYGVAYVSAYYEY., wherein said first and said second immunoglobulin single variable domains are covalently linked by a linker peptide, wherein said linker peptide comprises a third immunoglobulin single variable domain which binds to albumin comprising SEQ ID NO:24.